a b s t r a c t ATP sensitive potassium (K ATP ) channels connect the metabolic and energetic state of cells due to their sensitivity to ATP and ADP concentrations. K ATP channels have been identified in multiple tissues and organs of the body including heart, pancreas, vascular smooth muscles and skeletal muscles. These channels are obligatory hetero-octamers and contain four sulfonylurea (SUR) and four potassium inward rectifier (K ir ) subunits. Based on the particular type of SUR and K ir present, there are several tissue specific subtypes of K ATP channels, each with their own unique set of functions. Recently, K ATP channels have been reported in human and mouse ocular tissues. In ex vivo and in vivo model systems, K ATP channel openers showed significant ocular hypotensive properties with no appearance of toxic side effects. Additionally, when used in conjunction with known intraocular pressure lowering drugs, an additive effect on IOP reduction was observed. These K ATP channel openers have also been reported to protect the retinal ganglion cells during ischemic stress and glutamate induced toxicity suggesting a neuroprotective property for this drug class. Medications that are currently used for treating ocular hypertensive diseases like glaucoma do not directly protect the affected retinal cells, are sometimes ineffective and may show significant side effects. In light of this, K ATP channel openers with both ocular hypotensive and neuroprotective properties, have the potential to develop into a new class of glaucoma therapeutics.
Introduction
ATP sensitive potassium (K ATP ) channels are evolutionarily conserved membrane proteins that connect the metabolic and energetic state of cells by virtue of their sensitivity to micromolar concentrations of intracellular ATP and ADP . K ATP channels have been reported in multiple organs and tissues of the body including heart (Noma, 1983) , pancreas (Ashcroft et al., 1984; Cook and Hales, 1984) , brain (Ashcroft et al., 1984; Ashford et al., 1988) , pituitary gland (Bernardi et al., 1993) and skeletal (Spruce et al., 1985) and smooth muscles (Standen et al., 1989) . K ATP channels perform a multitude of functions but because of their sensitivity to ATP and ADP concentrations, these channels are often linked to changes in cellular metabolic states such as ischemia and hypoxia (Rodrigo and Standen, 2005) . One of the most well understood functions of K ATP channels is in regulation of insulin secretion from the pancreatic beta cells (Proks and Lippiat, 2006) . In other organs such as heart and brain, the functions of K ATP channels are mostly protective in nature (Gross and Auchampach, 1992; Parratt and Kane, 1994; Rodrigo and Standen, 2005) .
K ATP channels have recently been identified in tissues of the anterior and posterior chambers of human and mouse eyes (Chowdhury et al., 2013; Roy Chowdhury et al., 2015a) . The presence of these channels and the effects of K ATP channel openers and closers have suggested a role in intraocular pressure regulation (Chowdhury et al., 2011 (Chowdhury et al., , 2013 Roy Chowdhury et al., 2015a) . Additionally, K ATP channels have been shown to be involved in protecting retinal cells in the presence of ischemic stress or glutamate induced toxicity (Atlasz et al., 2007; Roth et al., 2003 Roth et al., , 2006 . In this review we summarize the salient features of K ATP channels and highlight recent studies suggesting that pharmacologic openers of K ATP channels such as diazoxide, nicorandil and cromakalim may be a new class of ocular hypotensive agents.
2. Molecular structure of K ATP channels K ATP channels are transmembrane octameric proteins formed from two separate subunits, the regulatory sulfonylurea (SUR) subunit and the pore forming potassium inward rectifier (K ir ) subunit (Fig. 1A ) Aguilar-Bryan et al., 1995; Inagaki et al., 1995c) . The SUR subunits are coded by two separate genes in humans e SUR1 and SUR2 (Chutkow et al., 1996; Inagaki et al., 1995a) . The initial SUR gene (ABCC8) was mapped to chromosome band 11p15.1 and its protein product (SUR1) was identified based on studies utilizing glibenclamide, a sulfonylurea compound that inhibited K ATP channel activity (Thomas et al., 1995; Aguilar-Bryan et al., 1995) . A second SUR gene (ABCC9) was identified at chromosome locus 12p12.1. The ABCC9 gene gives rise to two separate subunits e SUR2A and SUR2B, through alternate splicing (Chutkow et al., 1996) . SUR2A and SUR2B are identical except for the terminal 42 amino acid residues (Fig. 1B) . (AguilarBryan et al., 1998 ) Both SUR1 and SUR2 are members of the ATP binding cassette (ABC) transporter superfamily, a common membrane protein found in all species that use energy from ATP hydrolysis to selectively translocate specific molecules across the cell membrane (Higgins and Linton, 2001; Tucker and Ashcroft, 1998) . Similar to other ABC proteins, the SUR subunits contain two nuclear binding domains and two consensus nucleotide binding motifs (Conti et al., 2001) . Mutations in the ABCC8 gene are known to cause hyperinsulinemic hypoglycemia in infants and have been linked to type II diabetes (Laukkanen et al., 2004; Lohmueller et al., 2003; Meirhaeghe et al., 2001) , while mutations in the ABCC9 gene have been identified in sporadic cases of dilated cardiomyopathy, atrial fibrillation and hypertrichotic osteochondrodysplasia (Bienengraeber et al., 2004; Harakalova et al., 2012; Olson et al., 2007; van Bon et al., 2012) .
Initial studies with SUR1 and several known inward rectifiers (e.g. ROMK1, IRK1 etc.) (Ho et al., 1993; Makhina et al., 1994) failed to produce channel activity (Aguilar-Bryan et al., 1995) , suggesting that additional subunits were necessary to form functional K ATP channels. This led to the cloning of KCNJ8 (12p11.23) and KCNJ11 (11p15.1), which code for K ir 6.1 and K ir 6.2 (Inagaki et al., 1996 (Inagaki et al., , 1995a (Inagaki et al., , 1995b Isomoto et al., 1996; Yamada et al., 1997) . Mutations in the KCNJ8 or KCNJ11 genes can lead to impaired cardiac adaptation to stress, heart disease (Gumina et al., 2007; Hodgson et al., 2003; Yamada et al., 2006) or an increased susceptibility to endotoxemia . This has been found to be true in both mice and humans Kane et al., 2005) . The amino acid sequences of K ir 6.1 and K ir 6.2 have approximately 70% homology and share around 40e50% similarity with other K ir channels. Like the SUR subunits, K ir 6.1 and K ir 6.2 failed to yield K þ currents on their own (Aguilar-Bryan et al., 1995; Inagaki et al., 1995a) . However, combination of SUR and K ir subunits forms active K ATP channels (Inagaki et al., 1996) . SUR subunits contain nuclear binding domains and possess intrinsic ATPase activity making them the chief regulatory subunits that respond to intracellular metabolic changes (Olson and Terzic, 2010) . The SUR's nuclear binding domains can also attach to Mg-ADP, subsequently activating the subunits. Therefore, the hydrolysis of Mg-ATP by one of the nuclear binding domains can provide ADP for a separate nuclear binding domain to initiate channel activation (Ueda et al., 1997 Zingman et al., 2001) , increasing the probability of maximum channel activation in the absence of ATP (Babenko et al., 1999) . The K ir subunits can also bind with ATP but unlike SUR, they do so in the absence of Mg 2þ and with much less affinity than that of a complete channel (Tanabe et al., 1999 (Tanabe et al., , 2000 . The SUR and K ir subunits interact through various transmembrane domains (Doyle et al., 1998; Kuo et al., 2003; Nishida and MacKinnon, 2002) . Functionally, the K ir subunit is involved in forming the channel pore while the SUR subunit is the main regulatory site, responsible for pharmacologic characteristics of the channels (Aguilar-Bryan et al., 1995; Inagaki et al., 1995a; Sakura et al., 1995) . SURs form the regulatory subunit and are named due to their affinity for sulfonylureas which block the channel. The K ir subunits form the pore forming unit which allows selective translocation of K þ ions based on metabolic states of the cell. Depending on the particular SUR and K ir subunit combination, there can be six different sub-types of K ATP channels.
These sub-types are tissue specific and have varied specificity towards pharmacologic openers and closers of these channels. (B) SUR2A and SUR2B are both translated from the SUR2 gene and have 99% homology. The two subunits differ only in the last 42 amino acid residues (blue box) in the C-terminus. This is due to alternative splicing of the two 3 0 terminal exons of the SUR2 gene.
Localization and functions
Depending on the particular SUR and K ir subunits, there can be a total of 6 different subtypes of K ATP channels. These subtypes are often tissue specific and can have characteristic functionalities of their own (Rodrigo and Standen, 2005) . In this section, we briefly describe the subunit composition and associated function of K ATP channels in heart, muscles and pancreas where they have been studied in detail. For more information regarding K ATP function in other tissues, readers may refer to the reviews by Rodrigo and Standen and Seino and Miki (Rodrigo and Standen, 2005; Seino and Miki, 2003) .
Cardiac tissue
In cardiac tissue, K ATP channels are comprised of SUR2A and K ir 6.2 subunits (Ashcroft and Ashcroft, 1990; Inagaki et al., 1996) . These channels protect cardiac cells from Ca 2þ overload, control cellular relaxation and are vital during ischemic episodes (Noma, 1983; Ganote, 1983; Nichols and Lederer, 1991) .
Vascular smooth muscle
In vascular smooth muscles, K ATP channels are composed of SUR2B and K ir 6.1 subunits. These channels have less affinity to inhibition by intracellular ATP but respond strongly to nucleoside diphosphates (Beech et al., 1993; Quayle et al., 1997) , likely due to rather static ATP levels in vascular smooth muscle tissues except during extreme metabolic stress (Rodrigo and Standen, 2005) . As a result, ATP inhibition occurs at much lower levels in SUR2B and K ir 6.1 containing vascular K ATP channels. The vascular K ATP channels help in regulating blood flow by sensing various metabolic parameters like pH, adenosine levels and oxygen tension. Therefore it is not surprising that SUR2B and K ir 6.1 subunit containing channels play an important role in body homeostasis during periods of high metabolic activity like physical exercise . A similar protective function during physical stress is also exhibited by K ir 6.2 subunit containing K ATP channels of the heart (Olson and Terzic, 2010; Zingman et al., 2002) .
Skeletal muscle
One of the predominant roles of K ATP channels in skeletal muscles is to increase vasodilation and formation of nitric oxide (Marshall, 2000) , particularly during fatigue (Light et al., 1994) . These channels are composed of SUR2A and K ir 6.2 (Allard and Lazdunski, 1993; Forestier et al., 1996) and their degree of inhibition by ATP is strongly regulated by changes in pH (Davies et al., 1992) . Similar to K ATP channels present in other tissues, activation of these channels in skeletal muscles protects cells from excess Ca 2þ accumulation, subsequently regulating contractile properties (Burton and Smith, 1997; Matar et al., 2000; Seino and Miki, 2003) . Additionally, studies in K ir 6.2 (À/À) mice indicate a regulatory role for K ATP channels in cellular glucose absorption in skeletal muscles (Miki et al., 1998) .
Pancreas
K ATP channels of the pancreas are composed of SUR1 and K ir 6.2 subunits (Inagaki et al., 1995a) and play a major role in regulating insulin secretion and subsequently glucose metabolism in the whole body. In pancreatic b cells, inhibition of K ATP channels by ATP causes membrane depolarization that generates an associated voltage gated Ca 2þ influx. Once the depolarization exceeds a cell specific threshold (Ashcroft and Rorsman, 2013; Rorsman et al., 2011) , insulin is released through exocytosis of intracellular granules (Schulla et al., 2003) . K ATP channels have also been reported to affect glucagon secretion by a cells of the pancreas (Gromada et al., 2004; Shiota et al., 2005) . Both gain and loss of function mutations have been identified in the K ATP channels of the pancreatic islets. Gain of function mutations in SUR1 or K ir 6.2 cause neonatal diabetes mellitus and loss of function mutations in these subunits cause congenital hyperinsulinism where insulin is constitutively secreted despite low levels of blood glucose (Huopio et al., 2003; Ocal et al., 2011) . K ATP channel mutations have also been reported as causal for type 2 diabetes mellitus (Gloyn et al., 2003; Sakura et al., 1995) .
Pharmacologic openers and closers of K ATP channels
Pharmacologic agents that affect the activation (opening) and inhibition (closing) of K ATP channels have played an important role in understanding the functional significance of K ATP channels. As such, many of these agents are used clinically to treat a multitude of disorders. K ATP channel openers such as diazoxide, nicorandil and cromakalim have been used to treat hypertension, myocardial ischemia, bronchial asthma, urinary incontinence, hyperinsulinism, angina pectoris and some forms of skeletal muscle myopathies (Hibino et al., 2010) . In contrast, K ATP channel closers stimulate insulin secretion and therefore pharmacologic closers like glibenclamide are one of the only oral medicines to treat diabetes. More recently, development of K ATP channel closers called PNU compounds (PNU-37883A, a morpholinoguanidine and PNU-99963, a cyanoguanidine) have been shown to inhibit the vasodilation and hypotension caused by traditional K ATP channel openers (Khan et al., 1997; Meisheri et al., 1993) .
In general, activation of K ATP channels leads to membrane hyperpolarization whereas K ATP channel closers cause depolarization of the cell membrane. However, K ATP channel openers and closers are often specific for the subunit combination and hence have diverse roles based on the involved tissue. This specificity appears to be due to allosteric interactions involving the binding domains of the openers and closers with the nuclear binding domains of the SUR subunits. Diazoxide acts on SUR1 and SUR2B containing channels and can activate SUR2A channels only in the presence of MgADP (Ashcroft and Gribble, 2000; Hibino et al., 2010; Isomoto et al., 1996; Yamada et al., 1997) . Because of its specificity for SUR1 and SUR2B subunits, diazoxide is used to treat uncontrolled insulin secretion in conditions like persistent hyperinsulinemic hypoglycemia in infants (Hibino et al., 2010) . Nicorandil specifically activates SUR2B containing K ATP channels and by virtue of its vasodilating actions through vascular smooth muscles, is used to treat angina without affecting the SUR1 containing pancreatic b cells.
K ATP channel closers glibenclamide and meglitinide block both SUR1 and SUR2 channels with equal efficacy whereas SUR1 selective blockers like tolbutamide have low affinity for SUR2 containing channels (Gribble and Reimann, 2003; Hibino et al., 2010; Rodrigo and Standen, 2005) .
Distribution of K ATP channels and their electrophysiological properties in ocular cells and tissues
To evaluate the ocular hypotensive properties of K ATP channel openers, it was essential to demonstrate the presence of functional K ATP channels in the relevant ocular tissues. For this purpose we restricted our search to the trabecular meshwork and tissues of the anterior chamber as the primary regulatory units of the conventional outflow pathway. Patch clamp studies performed on isolated primary normal trabecular meshwork cells from human donors showed that channel opening probability at À60 mV increased from 0.29 ± 0.05 to 0.62 ± 0.05 in the presence of the K ATP channel opener diazoxide (Fig. 2) . Additionally, the current magnitude increased from 1.68 ± 0.29 pA to 3.34 ± 0.35 pA (Chowdhury et al., 2011) . K ATP channel activity was attenuated when glibenclamide (K ATP channel closer) was added to the cells, confirming the presence of functional K ATP channels in normal trabecular meshwork cells (Fig. 2) .
Among the various subunits, SUR2A, SUR2B, K ir 6.1 and K ir 6.2 mRNAs were identified in human trabecular meshwork tissue as well as primary cultures of normal human trabecular meshwork cells but SUR1 was not detected (Chowdhury et al., 2011) . At the protein level, antibodies for the specific subunits identified SUR2B, K ir 6.1 and K ir 6.2 in human trabecular meshwork and Schlemm's canal tissue (Fig. 3AeE) . In mouse, tissues in the anterior chamber including the cornea, iris, ciliary body, trabecular meshwork and Schlemm's canal were all positive for SUR2B, K ir 6.1 and K ir 6.2 (Fig. 3FeJ) (Chowdhury et al., 2011 (Chowdhury et al., , 2013 . Although SUR2A mRNA was detected, this subunit stained negative in immunohistochemistry of human and mouse ocular tissues ( Fig. 3B and G) . The reason behind this discrepancy is unclear, but could be reasonably explained by the inability of the SUR2A commercial antibody to recognize the subunit or alternatively, SUR2A could be minimally expressed on cell membranes. Nevertheless, it is clear that multiple K ATP channel subunits are present in various tissues in human and mouse eyes.
K ATP channel openers as ocular hypotensive agents
Glaucoma is a progressive neurodegenerative disorder and the leading cause of irreversible blindness worldwide (Quigley and Broman, 2006; Weinreb et al., 2014) . By the year 2040 an estimated 110 million people will be affected by the disease (Tham et al., 2014) . Among various risk factors of glaucoma, elevated IOP is the only one that can be therapeutically modified. As a result, all treatment options for the disease e both pharmacological and surgical e are aimed at lowering IOP (Heijl et al., 2002) . Unfortunately, all current drugs used to treat glaucoma (e.g. prostaglandin analogs, carbonic anhydrase inhibitors, b blockers, etc.) are associated with side effects (Roy Chowdhury et al., 2015b) . Contraindicative symptoms include hypertrichosis, allergic conjunctivitis, hyperemia, blurred vision and even severe systemic cardiovascular episodes, particularly with b-blockers (Aydin Kurna et al., 2014; Diggory and Franks, 1996; Johnstone, 1997; Mandell et al., 1988; Nguyen, 2014; Roy Chowdhury et al., 2015b; Wistrand et al., 1997) . Additionally, no current therapeutics to treat glaucoma specifically targets the trabecular meshwork which is in part due to the incomplete understanding of the disease pathogenesis (Weinreb et al., 2014; Weinreb and Khaw, 2004) . Therefore, searching for novel drugs that can help treat the disease by addressing underlying physiologic events is of particular importance (Crooke et al., 2012) . Over the past five years, our laboratory has published several studies showing a novel ocular hypotensive property of K ATP channel openers (Chowdhury et al., 2011 (Chowdhury et al., , 2013 Roy Chowdhury et al., 2015a) . In the following paragraphs, we review the experimental evidence and discuss the potentials and pitfalls of developing the K ATP channel openers into a future therapeutic drug for treating glaucoma.
In non-ocular cells, the opening and closing of K ATP channels modulates cellular contractility, cell adhesion, gap and tight junction regulation, adaptation to stress (shear, stretch, pressure, and oxidation), and improves overall cell well-being (Brayden, 2002; Chatterjee et al., 2003; Dal-Secco et al., 2008; Gao et al., 2009; Kane et al., 2004 Kane et al., , 2005 Kawamura et al., 2005; Nichols and Lederer, 1991; O'Donnell et al., 1995; Ozcan et al., 2007; Seino and Miki, 2003; Standen et al., 1989; Zingman et al., 2002 Zingman et al., , 2003 . Interestingly, all these processes have been implicated in altering outflow facility in the eye and therefore in the pathophysiology of glaucoma. However, the role of K ATP channels in ocular tissues has never been studied. We reasoned that in light of this functional relevance of K ATP channels to the underlying events leading to glaucoma, these channels may also have a role in IOP regulation. To determine whether the opening of K ATP channels had an effect on the trabecular meshwork and intraocular pressure regulation, we added K ATP channel openers diazoxide, nicorandil and cromakalim to human anterior segment perfusion organ cultures. Diazoxide, nicorandil and cromakalim all showed reduction in pressure (diazoxide, 41%; nicorandil, 35%; cromakalim, 31%; pressure reduction compared to baseline) and outflow facility (80% with diazoxide; 50% for nicorandil; 50% with cromakalim) (Fig. 4AeC) . (Chowdhury et al., 2011 (Chowdhury et al., , 2013 Roy Chowdhury et al., 2015a) . In comparison, latanoprost free acid, which is the active component of the glaucoma drug xalatan, increased outflow facility by 67% in this model (Bahler et al., 2008) . Pressure reduction with K ATP channel openers was reversible and was completely inhibited by the K ATP channel closer glibenclamide (Fig. 4D) . For in vivo assessment, eye drops containing diazoxide or cromakalim were applied topically to one eye of wild type C57BL/6 mice once daily, while the contralateral eye received vehicle. Over a 14-day treatment period, diazoxide lowered IOP by 22% (maximal reduction of 25% on day 7) while cromakalim lowered IOP by 19% Fig. 3 . Immunohistochemical localization of K ATP channel subunits in tissues of the conventional outflow pathway. (AeE) In normal human trabecular meshwork tissue, SUR2B, K ir 6.1 and K ir 6.2 were present while SUR1 and SUR2A were absent. (FeJ) In mouse eyes, results similar to human studies were obtained e SUR2B, K ir 6.1 and K ir 6.2 were present while SUR1 and SUR2A were absent. Some auto-fluorescence was observed with SUR1 and SUR2A antibodies but the overall intensity was much lower than the subunits that stained positive. SUR2B, K ir 6.1 and K ir 6.2 were evenly distributed in the trabecular meshwork (TM), ciliary body (CB), iris (I) and inner and outer wall of Schlemm's canal (SC). AC, anterior chamber. following a 5 day treatment period (maximal reduction of 23% on day 5) (Fig. 5A and B) (Chowdhury et al., 2011 (Chowdhury et al., , 2013 Roy Chowdhury et al., 2015a) , all slightly better than normotensive mice eyes treated with latanoprost, which produced an 18% IOP reduction when compared to control eyes (Akaishi et al., 2009; Ota et al., 2005) . Histologically, tissues of the conventional outflow pathway appeared normal in both human anterior segment cultures and in mouse eyes following treatment showing intact trabecular beams with viable trabecular meshwork cells and intact Schlemm's canal inner and outer walls with healthy appearing cells. This suggests that treatment with pharmacologic K ATP channel openers appears to be safe since no toxic side effects were observed ( Fig. 5C and D) . (Chowdhury et al., 2011 (Chowdhury et al., , 2013 Roy Chowdhury et al., 2015a) .
Besides ocular hypotensive activity, the ability of a novel drug to work with existing glaucoma therapeutics to additively lower IOP would be a significant benefit in treating glaucoma. We have shown that cromakalim produces an additive IOP reduction when used in combination with the free acid form of latanoprost. For example, when C57BL/6 wild type mice were treated with both cromakalim and latanoprost, IOP was lowered by an additional 79% compared to cromakalim alone (Fig. 6A) and 56% compared to latanoprost alone ( Fig. 6B ) (Roy Chowdhury et al., 2015a) . Ongoing studies are defining a novel signaling pathway distinct from latanoprost that is used by K ATP channels to lower IOP (manuscript under preparation).
Subunit composition of K ATP channels involved in lowering IOP
Since heterogeneity of K ATP channels imparts selective specificity to the various pharmacologic openers, it is important to understand the particular subunit composition of the K ATP channels involved in lowering IOP. To determine subunit specificity, we obtained K ir 6.2 (À/À) mice from Dr. Andre Terzic (Mayo Clinic). These mice are phenotypically normal, reproduce and live long lives similarly to wild-type controls. Other than a defective insulin secretion, these mice do not exhibit any major health issues under normal conditions (Miki et al., 1998; Seino et al., 2000; Zingman et al., 2002) . Only during cardiac adaptation in the event of physiologic stress (e.g. excessive physical exercise) do the animals encounter premature cardiac problems (Zingman et al., 2002 . In the eye, K ir 6.2 (À/À) mice looked normal at the levels of morphology and histology. The IOP in K ir 6.2 (À/À) mice tends to be normal when compared to littermate controls indicating that the K ir 6.2 subunit is not required for pressure regulation under homeostatic conditions (Chowdhury et al., 2013) . Treatment of K ir 6.2 (À/À) mice with diazoxide or cromakalim failed to lower IOP when compared to wild-type mice ( Fig. 5A and B ). This indicates that K i r6.2 subunit containing channels are essential for K ATP channel mediated reduction of IOP. Since diazoxide and nicorandil act mainly on SUR2B containing K ATP channels and have little or no effect on SUR2A channels (Lawson, 2000; Yokoshiki et al., 1998; Vivaudou et al., 2010) , we concluded that K ATP channels containing both K ir 6.2 and SUR2B were the essential subunits required for IOP regulation.
K ATP channels and neuroprotection of the retina
In addition to the ocular hypotensive effects of diazoxide, nicorandil and cromakalim, several reports have also indicated that K ATP channel openers have a neuroprotective function in the eye. Opening of retinal K ATP channels by diazoxide mimics ischemic preconditioning by activating downstream transduction of nitric oxide, particularly in the retinal ganglion cells (Roth et al., 2006) . Retinal ischemic preconditioning as seen by diazoxide treatment, can significantly decrease damage to the retina by inducing tolerance to ischemic events (Roth et al., 1998) . Diazoxide has also been shown to protect retinal degeneration caused by glutamate toxicity (Atlasz et al., 2007) . The neuroprotective effects of the K ATP channel opener diazoxide is particularly interesting due to the fact that none of the current ocular hypotensive agents used for treating glaucoma has a direct cell protective effect on the retina.
Future direction with K ATP channel openers
With excellent ocular hypotensive activity identified for K ATP channel openers, the next logical step is to proceed to clinical trials. However, a significant roadblock to using K ATP channel openers as a therapeutic for ocular hypertension is the insolubility of commercially available K ATP channel openers in therapy friendly aqueous buffers. At present, diazoxide and cromakalim are soluble in dimethyl sulfoxide or other organic solvents which are not appropriate for topical application to human eyes. In addition, nicorandil has vasodilator activity attributed to a nitrate group in its chemical structure (Nakae et al., 2000) , making it a problematic compound to test the hypothesis that K ATP channel openers lower IOP clinically in humans. In light of this, our laboratory has developed prodrugs based on the structure of the levo optical isomer of cromakalim. These novel prodrugs are aqueous soluble and on application to mouse eyes, are cleaved to generate the parent compound levcromakalim (unpublished data). The cromakalim prodrugs retain the IOP lowering ability of the parent compound and results are encouraging, with several prodrugs showing similar IOP reduction as the parent compound in mouse and rabbit eyes (unpublished data). Additional studies are underway in our laboratory to understand the IOP lowering abilities of these prodrugs as well as their pharmacokinetic profiles. Once completed, we intend to move one of these compounds forward into phase 1 clinical trials.
Concluding remarks
K ATP channels and their pharmacologic openers have important applications in a myriad of physiologic functions. K ATP channel openers have been shown to lower IOP in several experimental models including ex vivo human anterior segment cultures and in vivo mouse models. Additionally, other laboratories have shown that K ATP channel openers can protect retinal ganglion cells. Existing therapeutic strategies for treating glaucoma are often inadequate; come with unwanted side effects and none have direct neuroprotective properties, despite the fact that glaucoma is principally a disease of the retinal neurons. With the development of aqueous soluble prodrugs, K ATP channel openers have a strong potential to become a new class of glaucoma therapeutics that can lower IOP and directly protect the retinal ganglion cells and the optic nerve from neuronal degeneration caused by elevated IOP. 
